Combining noninvasive brain stimulation with behavioral pharmacology methods to study mechanisms of substance use disorder.
Michael J Wesley, Joshua A Lile
Frontiers in Neuroscience 2023 DOI: 10.3389/fnins.2023.1150109 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Population | Individuals with problematic cannabis use (described as the population of an ongoing study) |
| Intervention | Delta-9-tetrahydrocannabinol (THC) |
| Topics | Addiction Cannabis |
| Keywords | Behavioral pharmacology Brain stimulation Neural technology |
| Key points | Argues that combining human behavioral pharmacology methods with TMS can help establish links between neocortical function and addiction-related behavior, noting that the relationship between acute TMS neuromodulation of neocortex and direct effects on addiction-related behaviors is not well established. Describes an ongoing study testing whether left DLPFC stimulation alters THC's subjective and performance-impairing effects in people with problematic cannabis use. |
Abstract
Psychotropic drugs and transcranial magnetic stimulation (TMS) are effective for treating certain psychiatric conditions. Drugs and TMS have also been used as tools to explore the relationship between brain function and behavior in humans. Combining centrally acting drugs and TMS has proven useful for characterizing the neural basis of movement. This combined intervention approach also holds promise for improving our understanding of the mechanisms underlying disordered behavior associated with psychiatric conditions, including addiction, though challenges exist. For example, altered neocortical function has been implicated in substance use disorder, but the relationship between acute neuromodulation of neocortex with TMS and direct effects on addiction-related behaviors is not well established. We propose that the combination of human behavioral pharmacology methods with TMS can be leveraged to help establish these links. This perspective article describes an ongoing study that combines the administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive compound in cannabis, with neuroimaging-guided TMS in individuals with problematic cannabis use. The study examines the impact of the left dorsolateral prefrontal cortex (DLPFC) stimulation on cognitive outcomes impacted by THC intoxication, including the subjective response to THC and the impairing effects of THC on behavioral performance. A framework for integrating TMS with human behavioral pharmacology methods, along with key details of the study design, are presented. We also discuss challenges, alternatives, and future directions.
Citations in the library
Cites 7
- Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users. Experimental and Clinical Psychopharmacology June 2018
- Abnormal medial prefrontal cortex activity in heavy cannabis users during conscious emotional evaluation. Psychopharmacology March 1, 2016
- Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC. Drug and Alcohol Dependence April 1, 2012
- Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinol. Clinical Neuropharmacology 2010
- Acute marijuana effects on human risk taking. Neuropsychopharmacology April 2005
and 2 more in the library